Literature DB >> 20632148

[Rehabilitation in ankylosing spondylitis].

Martin Skoumal1, Guenther Haberhauer, Christoph Strehblow.   

Abstract

Modern treatment of patients with ankylosing spondylitis consists of therapies according to the ASAS criteria. Rehabilitation is a necessary process for enabling persons with disabilities caused by inflammatory destructions. The goal is to reach optimal physical, sensory, psychiatric and social health to reach higher levels of independence. It includes a wide range of measures and activities for changing the behaviour and increases activity, participation, strength, stability and coordination.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20632148     DOI: 10.1007/s10354-010-0794-1

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  6 in total

1.  ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; R Burgos-Vargas; E Collantes; J C Davis; B Dijkmans; M Dougados; P Géher; R D Inman; M A Khan; T K Kvien; M Leirisalo-Repo; I Olivieri; K Pavelka; J Sieper; G Stucki; R D Sturrock; S van der Linden; D Wendling; H Böhm; B J van Royen; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

2.  [Physical Therapy in the early treatment of ankylosing spondylitis].

Authors:  Erich Mur
Journal:  Wien Med Wochenschr       Date:  2008

Review 3.  [Radon within therapeutic strategies of ankylosing spondylitis].

Authors:  Manfred Herold; Gudrun Lind-Albrecht
Journal:  Wien Med Wochenschr       Date:  2008

4.  [Radon pit treatment of ankylosing spondylitis].

Authors:  R Günther; O Henn
Journal:  Verh Dtsch Ges Rheumatol       Date:  1969

5.  [Symptoms, effects on quality of life, judgement and expectations of treatment in active ankylosing spondylitis: the patient's view].

Authors:  A Falkenbach; B Curda
Journal:  Rehabilitation (Stuttg)       Date:  2001-10       Impact factor: 1.113

6.  [Spondylarthritides].

Authors:  J Braun; J Sieper
Journal:  Z Rheumatol       Date:  2006-11       Impact factor: 1.372

  6 in total
  1 in total

1.  [Seronegative spondylarthritis].

Authors:  Peter Fasching
Journal:  Wien Med Wochenschr       Date:  2010-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.